<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04343521</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00108666</org_study_id>
    <secondary_id>1U01AI148069-01</secondary_id>
    <nct_id>NCT04343521</nct_id>
  </id_info>
  <brief_title>Impact of Indoor Residual Spraying on Aedes-borne Diseases</brief_title>
  <official_title>Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial will be conducted in the city of Merida extending ongoing longitudinal cohort to&#xD;
      follow a population of 4,600 children 2-15 years old randomly allocated to receive either&#xD;
      TIRS treatment or not. If efficacious, TIRS will drive a paradigm shift in Aedes control by:&#xD;
      considering Ae. aegypti behavior to rationally guide insecticide applications; the change to&#xD;
      preventive control (pre- ABD transmission season rather than in response to symptomatic&#xD;
      cases); the use of third generation insecticides to which Ae. Aegypti is susceptible.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Contemporaneous urban vector control (truck-mounted ultra-low volume spraying, thermal&#xD;
      fogging, larviciding) has failed to contain dengue epidemics and to prevent the global range&#xD;
      expansion of Aedes-borne diseases (ABDs: dengue, chikungunya, zika). Part of the challenge in&#xD;
      sustaining effective ABD control emerges from the remarkable paucity of evidence about the&#xD;
      epidemiological impact of any vector control method. Furthermore, the classic deployment of&#xD;
      interventions in response to clinical cases fails to account for the important contribution&#xD;
      of out-of-home human mobility and asymptomatic infections.&#xD;
&#xD;
      The trial will be conducted in the city of Merida extending ongoing longitudinal cohort to&#xD;
      follow a population of 4,600 children 2-15 years old randomly allocated to receive either&#xD;
      TIRS treatment or not. If efficacious, TIRS will drive a paradigm shift in Aedes control by:&#xD;
      considering Ae. aegypti behavior to rationally guide insecticide applications; the change to&#xD;
      preventive control (pre- ABD transmission season rather than in response to symptomatic&#xD;
      cases); the use of third generation insecticides to which Ae. Aegypti is susceptible.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 3, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of laboratory confirmed (RT-PCR or IgM/IgG ELISA) symptomatic Aedes-borne Viruses in paired acute and convalescent samples</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Number of laboratory confirmed (RT-PCR or IgM/IgG ELISA) symptomatic Aedes-borne Viruses (DENV, CHIKV and ZIKV) in paired acute and convalescent samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of laboratory confirmed (IgG ELISA and neutralization testing) Aedes-borne Viruses cases in annual surveillance samples</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Number of laboratory confirmed (IgG ELISA and neutralization testing) Aedes-borne Viruses (DENV, CHIKV and ZIKV) in annual surveillance samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae. aegypti mosquito infection rate with Aedes-borne Viruses (DENV, CHIKV and ZIKV)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Ae. aegypti mosquito infection rate with Aedes-borne Viruses (DENV, CHIKV and ZIKV) assessed by RT-PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae. aegypti indoor entomological index adult presence/abundance</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Ae. aegypti indoor entomological index adult presence/abundance will be calculated. Presence of mosquitoes/house. The higher the value, the worst the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae. aegypti indoor entomological index female presence/abundance</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Ae. aegypti indoor entomological index female presence/abundance will be calculated. Number of mosquitoes/house. The higher the value, the worst the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae. aegypti indoor entomological index bloodfed female presence/abundance. Number of bloodfed females per house. The higher the value, the works the outcome.</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Ae. aegypti indoor entomological index bloodfed female presence/abundance will be calculated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4702</enrollment>
  <condition>Aedes-borne Diseases</condition>
  <condition>Dengue</condition>
  <condition>Chikungunya</condition>
  <condition>Zika</condition>
  <arm_group>
    <arm_group_label>Targeted Indoor Residual Spraying (TIRS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All households in Targeted Indoor Residual Spraying (TIRS) clusters will be offered the intervention, epidemiological and entomological evaluation will occur in the center of each cluster</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine Aedes-borne virus (ABV) prevention and control, no Targeted Indoor Residual Spraying (TIRS)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Targeted Indoor Residual Spraying (TIRS)</intervention_name>
    <description>Spraying of insecticide Actellic 300CS will start May-June and extend for 1-2 months. Residents will be asked to temporarily leave the house during treatment and wait 0.5-1 h for the product to dry before re-entering the house. Insecticide application will follow strict protocol developed in CDC-Emory-UADY collaboration.</description>
    <arm_group_label>Targeted Indoor Residual Spraying (TIRS)</arm_group_label>
    <other_name>Actellic 300CS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Household Level Inclusion Criteria:&#xD;
&#xD;
               -  Household is located within the bounds of a study cluster (5x5 city-block&#xD;
                  clusters).&#xD;
&#xD;
               -  City block has at least 60% premises that are residential.&#xD;
&#xD;
          2. Individual Level Inclusion Criteria:&#xD;
&#xD;
               -  2 or more and up to 15 years of age at the time of initial enrollment&#xD;
&#xD;
               -  Living in a house that consented to TIRS.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Household Level Exclusion Criteria:&#xD;
&#xD;
               -  Households where study personnel identify a security risk (i.e., site where drugs&#xD;
                  are sold, residents are always drunk or hostile)&#xD;
&#xD;
               -  Sites where no residents spend time during the day (i.e. work 7d a week outside&#xD;
                  the home).Inability for a resident to provide informed consent.&#xD;
&#xD;
               -  Non-residential places (e.g., businesses, schools, markets, etc.).&#xD;
&#xD;
          2. Individual Level Exclusion Criteria:&#xD;
&#xD;
               -  Less than 2 years of age or more than 15 years of age at the time of enrollment.&#xD;
&#xD;
               -  Not living in a house that consented to TIRS.&#xD;
&#xD;
               -  Having a medical condition that prevents implementation of study procedures.&#xD;
&#xD;
               -  Temporary visitor to household&#xD;
&#xD;
               -  Plans to leave study area within next 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gonzalo Vazquez Prokopec, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universidad Autonoma de Yucatan</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97203</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://www.prokopeclab.org/tirs-1</url>
    <description>link to project website</description>
  </link>
  <reference>
    <citation>Manrique-Saide P, Dean NE, Halloran ME, Longini IM, Collins MH, Waller LA, Gomez-Dantes H, Lenhart A, Hladish TJ, Che-Mendoza A, Kirstein OD, Romer Y, Correa-Morales F, Palacio-Vargas J, Mendez-Vales R, PÃ©rez PG, Pavia-Ruz N, Ayora-Talavera G, Vazquez-Prokopec GM. The TIRS trial: protocol for a cluster randomized controlled trial assessing the efficacy of preventive targeted indoor residual spraying to reduce Aedes-borne viral illnesses in Merida, Mexico. Trials. 2020 Oct 8;21(1):839. doi: 10.1186/s13063-020-04780-7.</citation>
    <PMID>33032661</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2020</study_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Gonzalo Vazquez-Prokopec</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Targeted Indoor Residual Spraying</keyword>
  <keyword>Children</keyword>
  <keyword>DENV</keyword>
  <keyword>CHIKV</keyword>
  <keyword>ZIKV</keyword>
  <keyword>Ae. aegypti mosquito</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, and appendices), will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Starting one year following conclusion of the trial. No end date.</ipd_time_frame>
    <ipd_access_criteria>Investigators who provide a methodologically sound proposal will get access to achieve aims in the approved proposal. Proposals should be directed to lwaller@emory.edu. To gain access, data requesters will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

